MX2012007474A - Derivados de 3-hidroxi-5-arilisotiazol novedosos. - Google Patents
Derivados de 3-hidroxi-5-arilisotiazol novedosos.Info
- Publication number
- MX2012007474A MX2012007474A MX2012007474A MX2012007474A MX2012007474A MX 2012007474 A MX2012007474 A MX 2012007474A MX 2012007474 A MX2012007474 A MX 2012007474A MX 2012007474 A MX2012007474 A MX 2012007474A MX 2012007474 A MX2012007474 A MX 2012007474A
- Authority
- MX
- Mexico
- Prior art keywords
- ring
- novel
- arylisothiazole
- hydroxy
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Problema. Proporcionar un agente que activa GPR40 que tiene, como un ingrediente activo, un compuesto novedoso que tiene una acción agonista GPR40, una sal del compuesto, un solvato de la sal o el compuesto, o similares, particularmente, un secretagogo de insulina y y un agente terapéutico y/o profiláctico contra diabetes, obesidad, u otras enfermedades. Medios para solucionar el problema Un compuesto de la Fórmula (I) (ver fórmula (I)) donde n es 0 hasta 2; p es 0 hasta 4; j es 0 hasta 3; k es 0 hasta 2; un anillo A es un grupo arilo que está opcionalmente sustituido con L o un grupo heterocíclico que está opcionalmente sustituido con L; un anillo B es un anillo de benceno, un anillo de piridina, o un anillo de pirimidina; X es O, S, -NR7-; y R1 hasta R7 son grupos específicos, una sal del compuesto, o un solvato de la sal o el compuesto.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009295855 | 2009-12-25 | ||
JP2010043420 | 2010-02-26 | ||
PCT/JP2010/073464 WO2011078371A1 (ja) | 2009-12-25 | 2010-12-24 | 新規3-ヒドロキシ-5-アリールイソチアゾール誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012007474A true MX2012007474A (es) | 2012-08-01 |
Family
ID=44195895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012007474A MX2012007474A (es) | 2009-12-25 | 2010-12-24 | Derivados de 3-hidroxi-5-arilisotiazol novedosos. |
Country Status (25)
Country | Link |
---|---|
US (1) | US8476287B2 (es) |
EP (1) | EP2518060A4 (es) |
JP (2) | JP5002077B2 (es) |
KR (1) | KR20130004262A (es) |
CN (2) | CN104710381A (es) |
AU (1) | AU2010336225A1 (es) |
BR (1) | BR112012015612A2 (es) |
CA (1) | CA2785674A1 (es) |
CL (1) | CL2012001722A1 (es) |
CO (1) | CO6650337A2 (es) |
CR (1) | CR20120345A (es) |
EA (1) | EA201290574A1 (es) |
EC (1) | ECSP12012056A (es) |
GT (1) | GT201200217A (es) |
HN (1) | HN2012001351A (es) |
IL (1) | IL220616A0 (es) |
MA (1) | MA33952B1 (es) |
MX (1) | MX2012007474A (es) |
NI (1) | NI201200113A (es) |
NZ (1) | NZ601408A (es) |
PE (1) | PE20121639A1 (es) |
RU (1) | RU2567755C2 (es) |
SG (1) | SG181961A1 (es) |
WO (1) | WO2011078371A1 (es) |
ZA (1) | ZA201203416B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2495238A4 (en) | 2009-10-30 | 2013-04-24 | Mochida Pharm Co Ltd | NEW 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE |
WO2011078371A1 (ja) | 2009-12-25 | 2011-06-30 | 持田製薬株式会社 | 新規3-ヒドロキシ-5-アリールイソチアゾール誘導体 |
US8581584B2 (en) * | 2010-05-26 | 2013-11-12 | Florida State University Research Foundation | Membrane proteins, mechanisms of action and uses thereof |
JP5809157B2 (ja) | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | 環状アミド誘導体 |
EA025380B1 (ru) | 2011-02-25 | 2016-12-30 | Мерк Шарп Энд Домэ Корп. | Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов |
BR112013027883A2 (pt) * | 2011-04-27 | 2017-08-08 | Mochida Pharm Co Ltd | novo derivado de 1-óxido de 3-hidroxiisotiazol |
US9072758B2 (en) | 2011-04-28 | 2015-07-07 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
WO2013154163A1 (ja) * | 2012-04-11 | 2013-10-17 | 持田製薬株式会社 | 新規5-アリール-1,2-チアジナン誘導体 |
SG10201704095UA (en) | 2012-04-24 | 2017-06-29 | Vertex Pharma | Dna-pk inhibitors |
JP2015522080A (ja) | 2012-07-11 | 2015-08-03 | エルセリクス セラピューティクス インコーポレイテッド | スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物 |
KR20150036245A (ko) | 2012-08-02 | 2015-04-07 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 트리시클릭 화합물 |
RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
CN107200749B (zh) | 2013-03-12 | 2019-09-03 | 沃泰克斯药物股份有限公司 | Dna-pk抑制剂 |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP3057953B1 (en) | 2013-10-17 | 2018-08-15 | Vertex Pharmaceuticals Incorporated | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
EP3068788A1 (en) | 2013-11-14 | 2016-09-21 | Cadila Healthcare Limited | Novel heterocyclic compounds |
JP6444525B2 (ja) * | 2015-02-27 | 2018-12-26 | ナントバイオ,インコーポレイテッド | キナーゼ阻害剤としてのピリミジン誘導体及びその治療用途 |
JP6616244B2 (ja) * | 2015-05-29 | 2019-12-04 | 北興化学工業株式会社 | 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法 |
TW201815418A (zh) | 2016-09-27 | 2018-05-01 | Vertex Pharma | 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法 |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
UA126458C2 (uk) | 2018-02-13 | 2022-10-05 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
TWI732245B (zh) | 2018-07-13 | 2021-07-01 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
CN110066254B (zh) * | 2018-11-16 | 2021-03-19 | 温州大学 | 一种异噻唑-3-酮化合物的制备方法 |
BR112022006546A2 (pt) | 2019-10-07 | 2022-08-30 | Kallyope Inc | Agonistas de gpr119 |
MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
CN115433143B (zh) * | 2021-06-03 | 2023-10-13 | 中国科学院大连化学物理研究所 | 一种异噻唑啉酮类化合物的合成方法 |
CN115386028B (zh) * | 2022-08-26 | 2023-06-23 | 长春理工大学 | 一种聚合度可控的聚山梨酸-d-薄荷醇酯及合成方法与应用 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3562283A (en) | 1968-07-01 | 1971-02-09 | Rohm & Haas | 1-oxo and 1,1-dioxo-3-isothiazolones |
US3801575A (en) * | 1972-01-24 | 1974-04-02 | Rohm & Haas | 3-hydroxyisothiazoles |
HUP9900400A3 (en) | 1996-02-27 | 2001-06-28 | Sankyo Company Ltd Chuo Ku | Isoxazole derivatives |
CZ20012528A3 (cs) | 1999-01-13 | 2002-06-12 | Warner-Lambert Company | 1-Heterocyklicky substituované diarylaminy, farmaceutické kompozice na jejich bázi a způsoby léčení |
JP2000204077A (ja) * | 1999-01-13 | 2000-07-25 | Warner Lambert Co | ジアリ―ルアミン |
AU2003263814A1 (en) | 2002-07-26 | 2004-02-16 | Bayer Pharmaceuticals Corporation | Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics |
US7553867B2 (en) | 2002-09-06 | 2009-06-30 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
CA2505322A1 (en) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
JP4594611B2 (ja) | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | 受容体機能調節剤 |
EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONNECTION WITH CONDENSED RING |
WO2005035551A2 (en) | 2003-10-08 | 2005-04-21 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
US7834013B2 (en) | 2003-11-19 | 2010-11-16 | Glaxosmithkline Llc | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40 |
RU2006126978A (ru) | 2003-12-25 | 2008-01-27 | Такеда Фармасьютикал Компани Лимитед (Jp) | Производные 3-(4-бензилоксифенил)пропановой кислоты |
ES2433466T3 (es) | 2004-02-27 | 2013-12-11 | Amgen, Inc | Compuestos, composiciones farmacéuticas y métodos para su uso en el tratamiento de trastornos metabólicos |
SE0500055D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
RU2008108984A (ru) | 2005-08-10 | 2009-09-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | Терапевтический агент от диабета |
AU2006291234A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
CN102731451B (zh) | 2006-06-27 | 2015-07-29 | 武田药品工业株式会社 | 稠环化合物 |
US7714008B2 (en) | 2006-09-07 | 2010-05-11 | Amgen Inc. | Heterocyclic GPR40 modulators |
WO2008033931A1 (en) | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib |
AU2007326395B2 (en) | 2006-12-01 | 2012-10-11 | Msd K.K. | Novel phenyl-isoxazol-3-ol derivative |
CA2683751C (en) | 2007-04-16 | 2013-01-08 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
NZ584049A (en) | 2007-09-21 | 2011-05-27 | Sanofi Aventis | (carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament |
AU2008311355B2 (en) | 2007-10-10 | 2012-01-19 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
JP2011016722A (ja) | 2007-10-23 | 2011-01-27 | Astellas Pharma Inc | チアゾリジンジオン化合物 |
TW200932219A (en) | 2007-10-24 | 2009-08-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
CL2008003153A1 (es) | 2007-10-26 | 2009-07-24 | Japan Tobacco Inc | Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras. |
WO2009111056A1 (en) | 2008-03-06 | 2009-09-11 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
EP2298750A4 (en) | 2008-06-02 | 2012-04-25 | Msd Kk | NOVEL ISOXAZOLE DERIVATIVE |
NZ588983A (en) | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
US20110312995A1 (en) | 2009-01-23 | 2011-12-22 | Schering Corporation | Bridged and fused heterocyclic antidiabetic compounds |
EP2393810A1 (en) | 2009-02-05 | 2011-12-14 | Schering Corporation | Phthalazine-containing antidiabetic compounds |
EP2440541A1 (en) | 2009-06-09 | 2012-04-18 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
EP2495238A4 (en) | 2009-10-30 | 2013-04-24 | Mochida Pharm Co Ltd | NEW 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE |
AR078948A1 (es) | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
WO2011078371A1 (ja) | 2009-12-25 | 2011-06-30 | 持田製薬株式会社 | 新規3-ヒドロキシ-5-アリールイソチアゾール誘導体 |
CN101781268B (zh) | 2010-02-25 | 2012-05-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 异噻唑酮取代的苯二羧酸衍生物及其用于制备β-分泌酶抑制剂的用途 |
JP5809157B2 (ja) | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | 環状アミド誘導体 |
-
2010
- 2010-12-24 WO PCT/JP2010/073464 patent/WO2011078371A1/ja active Application Filing
- 2010-12-24 CA CA2785674A patent/CA2785674A1/en not_active Abandoned
- 2010-12-24 EP EP10839599.7A patent/EP2518060A4/en not_active Withdrawn
- 2010-12-24 EA EA201290574A patent/EA201290574A1/ru unknown
- 2010-12-24 MX MX2012007474A patent/MX2012007474A/es active IP Right Grant
- 2010-12-24 CN CN201510033003.XA patent/CN104710381A/zh active Pending
- 2010-12-24 US US13/392,350 patent/US8476287B2/en not_active Expired - Fee Related
- 2010-12-24 JP JP2011547676A patent/JP5002077B2/ja not_active Expired - Fee Related
- 2010-12-24 SG SG2012047601A patent/SG181961A1/en unknown
- 2010-12-24 BR BR112012015612A patent/BR112012015612A2/pt not_active IP Right Cessation
- 2010-12-24 AU AU2010336225A patent/AU2010336225A1/en not_active Abandoned
- 2010-12-24 RU RU2012131840/04A patent/RU2567755C2/ru not_active IP Right Cessation
- 2010-12-24 PE PE2012000884A patent/PE20121639A1/es not_active Application Discontinuation
- 2010-12-24 KR KR1020127019581A patent/KR20130004262A/ko not_active Application Discontinuation
- 2010-12-24 MA MA35101A patent/MA33952B1/fr unknown
- 2010-12-24 CN CN201080059173.0A patent/CN102712610B/zh not_active Expired - Fee Related
- 2010-12-24 NZ NZ601408A patent/NZ601408A/en not_active IP Right Cessation
-
2012
- 2012-05-10 ZA ZA2012/03416A patent/ZA201203416B/en unknown
- 2012-05-17 JP JP2012113868A patent/JP2012153726A/ja active Pending
- 2012-06-22 CL CL2012001722A patent/CL2012001722A1/es unknown
- 2012-06-24 IL IL220616A patent/IL220616A0/en unknown
- 2012-06-25 NI NI201200113A patent/NI201200113A/es unknown
- 2012-06-25 GT GT201200217A patent/GT201200217A/es unknown
- 2012-06-25 CO CO12106432A patent/CO6650337A2/es not_active Application Discontinuation
- 2012-06-25 CR CR20120345A patent/CR20120345A/es unknown
- 2012-06-25 HN HN2012001351A patent/HN2012001351A/es unknown
- 2012-07-23 EC ECSP12012056 patent/ECSP12012056A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2785674A1 (en) | 2011-06-30 |
EP2518060A4 (en) | 2014-01-08 |
EA201290574A1 (ru) | 2012-12-28 |
MA33952B1 (fr) | 2013-01-02 |
CN102712610A (zh) | 2012-10-03 |
IL220616A0 (en) | 2012-08-30 |
RU2567755C2 (ru) | 2015-11-10 |
NI201200113A (es) | 2012-08-13 |
JP2012153726A (ja) | 2012-08-16 |
ZA201203416B (en) | 2013-08-28 |
BR112012015612A2 (pt) | 2016-03-15 |
CN104710381A (zh) | 2015-06-17 |
US20120157459A1 (en) | 2012-06-21 |
GT201200217A (es) | 2014-02-10 |
EP2518060A1 (en) | 2012-10-31 |
CR20120345A (es) | 2012-11-01 |
AU2010336225A1 (en) | 2012-08-16 |
KR20130004262A (ko) | 2013-01-09 |
JP5002077B2 (ja) | 2012-08-15 |
PE20121639A1 (es) | 2012-12-02 |
US8476287B2 (en) | 2013-07-02 |
ECSP12012056A (es) | 2012-10-30 |
RU2012131840A (ru) | 2014-01-27 |
WO2011078371A1 (ja) | 2011-06-30 |
CL2012001722A1 (es) | 2012-12-14 |
JPWO2011078371A1 (ja) | 2013-05-09 |
SG181961A1 (en) | 2012-08-30 |
HN2012001351A (es) | 2015-03-23 |
CO6650337A2 (es) | 2013-04-15 |
CN102712610B (zh) | 2015-03-04 |
NZ601408A (en) | 2013-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012007474A (es) | Derivados de 3-hidroxi-5-arilisotiazol novedosos. | |
AU2016202535B2 (en) | Fused heterocyclic compounds as sodium channel modulators | |
MX2011011028A (es) | Agonista del receptor beta de hormona tiroidea novedoso. | |
NZ601638A (en) | Dihydrofuran derivatives as insecticidal compounds | |
MX2011008501A (es) | Compuestos heterociclicos fusionados que contienen nitrogeno y su uso como inhibidores de la produccion de beta-amiloide. | |
MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
EA201391525A1 (ru) | Гликозидные производные и их применение для лечения диабета | |
UA97257C2 (en) | Indole derivatives | |
MY152972A (en) | Azabicyclo compound and salt thereof | |
ATE557024T1 (de) | Piperidinverbindungen als gpcr-agonisten | |
PE20120648A1 (es) | Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1 | |
NZ600837A (en) | 1,3,4-oxadiazole-2-carboxamide compound | |
ATE500222T1 (de) | Benzamid- und heteroarenderivate als cetp- inhibitoren | |
MX2010008363A (es) | Derivados de arilamida diazepinopirimidona sustituidos para el tratamiento de enfermedades neurodegenerativas causadas por la actividad anormal de gsk3-beta. | |
MX2010008361A (es) | Derivados de arilamida oxazepinopirimidona sustituidos. | |
CL2011002181A1 (es) | Compuestos ciclicos o heterociclicos (n,o,s) de derivados de fenil (heterociclil) fenil (metil,etil) amina, agonistas de gpr119 e inhibidores de dpp-iv; composicion farmaceutica; y su uso para el tratamiento de la diabetes tipo ii, obesidad, sindrome metabolico, tolerancia a la glucosa e hiperlipidemia, entre otras enfermedades. | |
MY152475A (en) | Fused ring compounds and use thereof | |
MA32723B1 (fr) | Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments | |
ECSP11010849A (es) | Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275) | |
EA201490754A1 (ru) | Производные карбамата/мочевины, содержащие пиперидиновые и пиперазиновые кольца, в качестве ингибиторов н3 рецептора | |
MY167569A (en) | Process for the preparation of 1-acyl-4-phenylsulfonylprolinamide derivatives and new intermediates | |
MX348979B (es) | Agente de control de enfermedades de las plantas. | |
MX343077B (es) | Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos. | |
NZ609596A (en) | Cyclohexane derivative compound | |
MX343165B (es) | Agonistas del receptor 5-ht4 para el tratamiento de demencia. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |